Research map: Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16–26 years in Japan: a randomised, double-blind, placebo-controlled trial

Back to the article

Papers in this map

  1. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis · Catherine de Martel · 2019 · 2493 citations · Cited by this paper
  2. Real-world effectiveness and impact of human papillomavirus vaccination in males: a comprehensive review · Andres F. Manrique · 2026 · Cites this paper
  3. The spread of sexually transmissible drug-resistant shigellosis in England: a genomic epidemiology study · 2026 · Related
  4. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males · Anna R. Giuliano · 2011 · 1150 citations · Cited by this paper
  5. Updated Global Action Plan on Antimicrobial Resistance · 2026 · Related
  6. HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia · Joel Michael Palefsky · 2011 · 947 citations · Cited by this paper
  7. The wider value of RSV prevention · 2026 · Related
  8. Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine · Suzanne Marie Garland · 2009 · 537 citations · Cited by this paper
  9. Research in brief · 2026 · Related
  10. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial · Warner King Huh · 2017 · 475 citations · Cited by this paper
  11. Genomic epidemiology of invasive meningococcal disease in Scotland before, during, and after the COVID-19 pandemic: a retrospective observational study · 2026 · Related
  12. International Anal Neoplasia Society's consensus guidelines for anal cancer screening · Elizabeth A. Stier · 2024 · 307 citations · Cited by this paper
  13. New partnership to support TB vaccine implementation · 2026 · Related
  14. A fixed sequence Bonferroni procedure for testing multiple endpoints · Brian L. Wiens · 2003 · 156 citations · Cited by this paper
  15. USA to end support of South Africa's HIV programmes · 2026 · Related
  16. Immunogenicity and Safety of a 9-Valent HPV Vaccine · Pierre Van Damme · 2015 · 137 citations · Cited by this paper
  17. Sabiha Essack—helping Africa lead the fight against AMR · 2026 · Related
  18. Immunogenicity and safety of the 9-valent HPV vaccine in men · Xavier Castellsagué · 2015 · 130 citations · Cited by this paper
  19. Indigenous Australians see surge in diphtheria cases · 2026 · Related
  20. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial · Stephen E Goldstone · 2021 · 124 citations · Cited by this paper
  21. Enrolment begins in the EBO-PEP trial in DRC · 2026 · Related
  22. Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virus‐Like‐Particle Vaccine · Anna R. Giuliano · 2007 · 120 citations · Cited by this paper
  23. Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old · Richard John Hillman · 2011 · 114 citations · Cited by this paper
  24. Exact power and sample size for vaccine efficacy studies · Ivan S. F. Chan · 1998 · 92 citations · Cited by this paper
  25. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men · Pierre Van Damme · 2016 · 83 citations · Cited by this paper
  26. Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types · Christine C. Roberts · 2014 · 76 citations · Cited by this paper
  27. 4-Valent Human Papillomavirus (4vHPV) Vaccine in Preadolescents and Adolescents After 10 Years · Daron G. Ferris · 2017 · 75 citations · Cited by this paper
  28. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men · Beibei Lu · 2011 · 63 citations · Cited by this paper
  29. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study · Hiroshige Mikamo · 2019 · 60 citations · Cited by this paper
  30. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries · Suzanne Marie Garland · 2018 · 53 citations · Cited by this paper
  31. Ten-Year Follow-up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety · Jaime Restrepo · 2023 · 52 citations · Cited by this paper
  32. An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study · Donna J. Ingles · 2015 · 44 citations · Cited by this paper
  33. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials · Lone Kjeld Petersen · 2017 · 34 citations · Cited by this paper
  34. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men · Anna R. Giuliano · 2021 · 32 citations · Cited by this paper
  35. Safety Concerns or Adverse Effects as the Main Reason for Human Papillomavirus Vaccine Refusal · Onyema Greg Chido‐Amajuoyi · 2021 · 28 citations · Cited by this paper
  36. Scientific approaches toward improving cervical cancer elimination strategies · Matti Lehtinen · 2024 · 28 citations · Cited by this paper
  37. Oral human papillomavirus (HPV) prevalence and genotyping among healthy adult populations in the United States and Europe: results from the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study · Laia Alemany · 2025 · 19 citations · Cited by this paper
  38. Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies · Anna R. Giuliano · 2025 · 9 citations · Cited by this paper
  39. Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies · Alfred J. Saah · 2017 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)